Cancer clinical trials in the region Occitanie

385 currently recruiting clinical trials
Region Occitanie

Phase 3 Breast cancer #NCT05696626 #2023-503708-10-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ESR
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Targeted therapy Hormone therapy
Excluded genetic anomalies
Other mutation
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Sermonix Pharmaceuticals Inc.
Phase 3 Amyloidosis #NCT07207811 #2024-518899-31-00
Required histologic types
Other
Required organ involvement status
Presence
Required organ involvements
Cardiac
19 recruiting sites
Novo Nordisk A/S
Phase 3 Lung cancer #NCT06312137 #2023-508012-35-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
10 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Prostate cancer #NCT06764485
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
Celgene
Phase 3 Brain tumors / Central nervous system tumors #NCT06556563 #2024-513550-30-00
Required histologic types
Gliomas
Required histologic sub types
Glioblastoma
Required number of previous lines of therapy
None
Required previous treatments
Surgery Chemotherapy Radiotherapy Radiochemotherapy
Excluded previous treatments
Systemic Treatment-Naive Immunotherapy
5 recruiting sites
NovoCure GmbH
Phase 3 Brain tumors / Central nervous system tumors #NCT06388733 #2024-513077-48-00
Required histologic types
Gliomas
Required histologic sub types
Glioblastoma
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
IDH1/2
Excluded previous treatments
Chemotherapy Radiotherapy Radiochemotherapy TTFields Other targeted therapy
10 recruiting sites
Ivy Brain Tumor Center
Phase 3 Brain tumors / Central nervous system tumors #NCT05904119
Required histologic types
Gliomas
Required histologic sub types
Glioblastoma
Required number of previous lines of therapy
1
Required previous treatments
Surgery Radiochemotherapy
Excluded genetic anomalies
IDH1/2
Excluded previous treatments
Systemic Treatment-Naive
10 recruiting sites
EORTC - Organisation Européenne pour la Recherche et le Traitement du Cancer
Phase 3 Brain tumors / Central nervous system tumors #NCT05476939 #2014-001929-32
Required histologic types
Gliomas
Required histologic sub types
Diffuse midline glioma grade IV
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Chemotherapy Radiotherapy
33 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3 Brain tumors / Central nervous system tumors #NCT05476939 #2014-001929-32
Phase inclusion - gliomes diffus de la ligne médiane non-DIPG
Required histologic types
Gliomas
Required histologic sub types
Diffuse midline glioma grade IV
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Chemotherapy Radiotherapy
33 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3 Lymphoma #NCT06006117 #2022-501810-77-00
Required histologic types
B cell lymphoma
Required histologic sub types
Marginal zone lymphoma
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min 50-60 ml/min 30-50 ml/min
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Chemotherapy Targeted therapy Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive Bispecific T-cell engager antibodies Allogeneic stem cell transplant
23 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)